AI Timing: Injection Day, Bloodwork and Estrogen Symptoms
AI timing, made clearer
Injection day or the day after? The checked research does not establish a best day for everyone taking anastrozole with testosterone. The prescription and the timing of your bloodwork matter more than matching two chart peaks.
A drug curve cannot tell you whether estrogen is high or low. Keep the dose history, blood result and symptoms together when reviewing treatment.
Dose history
What you took, and when
Blood sample
A measurement at one moment
Symptoms
What changed over time
Compare them with your clinician. None of these records replaces the other two.
The three questions to separate
Whether to use an AI
Start with the treatment reason, symptoms and interpreted results.
When to take it
Follow the actual prescription; there is no universal injection-day rule.
When to measure
Agree on sampling time and record time since both medicines.
For a concrete example, one testosterone-clinic study started selected men on anastrozole 0.5 mg three times weekly, then followed hormone results. It did not establish an injection-day advantage, a standard duration or a schedule everyone needs.
How long can an AI keep affecting estrogen?
Anastrozole reversibly inhibits aromatase. Exemestane irreversibly inactivates affected enzyme, so its effect is not restricted to the time the parent drug remains in plasma. Both have breast-cancer indications; their labels do not validate an AI schedule for performance-enhancing steroid use. Arimidex label; Aromasin label.
It is also incorrect to assume that estradiol cannot change until several weeks of a long ester have accumulated. Drug exposure and endocrine response can begin before steady state. “Wait six weeks no matter what” is not a clinical rule.
Can symptoms distinguish high from low estradiol?
Not reliably. Sexual symptoms, fatigue and mood changes are nonspecific, while breast symptoms or swelling may need evaluation for other causes. A “dry” appearance, poor gym pump or sore joint is not an estradiol assay.
Record what changed and when rather than self-categorizing the problem as high or low estrogen. Severe symptoms should not wait for a planned routine blood draw.
Make the blood result comparable
| Record with the result | Why it helps |
|---|---|
| Assay and laboratory | Different methods can produce different values, especially at low concentrations |
| Units and reference interval | A number without units cannot be compared safely |
| Time since testosterone and AI doses | A changed sampling point can mimic a treatment change |
| Recent regimen changes | The result may reflect a transition rather than a settled pattern |
| Symptoms and other medicines | The hormone number is only part of the assessment |
An appropriate assay and consistent timing are useful; a fixed “all immunoassays over-read by 20–40%” rule is not. If a result conflicts with the clinical picture, a clinician can review the method or repeat it rather than calculating a DIY correction. Endocrine Society assay statement
Can estrogen go too low?
A randomized study in older men found that anastrozole increased testosterone while spine bone density decreased relative to placebo. Its population and duration matter, but it clearly shows why a higher testosterone number does not make estrogen suppression automatically beneficial. One-year bone-density trial
A small exemestane study also separated drug concentration from the timing of maximal estradiol suppression. It was short research in young males, not a long-term cycle-management protocol. Mauras et al.
Common questions
Should an AI always be taken on injection day? The sources here do not establish that rule.
Should I change the dose after one unexpected result? Confirm what the result means with the prescriber, including sampling time and assay. Do not make a large adjustment from an isolated unexplained value.
Can I use the plotter to diagnose an estrogen crash? No. It models drug exposure, not your estradiol production or symptoms.
See Arimidex vs Aromasin for the mechanism comparison.
Sources and review notes
Checked October 12, 2026. The clinical series describes selected patients, not a randomized comparison of injection-day versus next-day AI timing. The visual separates types of information; it is not a dosing calendar.
- Punjani et al., 2021: selected men receiving testosterone and anastrozole.
- Arimidex prescribing information and Aromasin prescribing information: product mechanisms and indication-specific information.
- Estradiol measurement position statement: assay limitations, particularly at low concentrations.
- Burnett-Bowie et al., 2009: one-year bone-density trial in older men.
- Mauras et al., 2003: short study of exemestane in young males.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.